Provided by Tiger Trade Technology Pte. Ltd.

TransCode Therapeutics Inc.

1.55
-0.1350-8.04%
Post-market: 1.53-0.0147-0.95%18:14 EDT
Volume:16.71K
Turnover:26.52K
Market Cap:26.16M
PE:-0.03
High:1.74
Open:1.67
Low:1.52
Close:1.68
52wk High:20.99
52wk Low:1.52
Shares:16.93M
Float Shares:2.15M
Volume Ratio:0.82
T/O Rate:0.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-50.6904
EPS(LYR):-52.5900
ROE:-59.28%
ROA:-19.90%
PB:-0.94
PE(LYR):-0.03

Loading ...

TransCode Therapeutics Eases Near-Term Obligations Under Financing

TIPRANKS
·
2 hours ago

TransCode Therapeutics Makes $840,975 Prepayment to Yorkville on Convertible Notes, Waiving Amortization Event Through Oct. 31

Reuters
·
2 hours ago

Transcode Therapeutics reports updated results from Phase 1a TTX-MC138 trial

TIPRANKS
·
Sep 28

TransCode Says Phase 1a Trial Shows 71.4% Stable Disease Rate for TTX-MC138 in Advanced Solid Tumors

Reuters
·
Sep 28

Transcode Reports Continued Disease Stabilization and Extended Treatment Duration with Ttx-Mc138 in Ongoing Phase 1a Clinical Trial Follow-up

THOMSON REUTERS
·
Sep 28

Transcode Therapeutics - Three Patients Remain Progression-Free at One Year

THOMSON REUTERS
·
Sep 28

Transcode Therapeutics - no Dose-Limiting Toxicities Reported Across Evaluated Dose Levels

THOMSON REUTERS
·
Sep 28

Transcode Therapeutics - 57.1% Disease Control Rate Through Three Months of Therapy

THOMSON REUTERS
·
Sep 28

Transcode Therapeutics - 71.4% Stable Disease Rate in 14 Efficacy-Evaluable Patients

THOMSON REUTERS
·
Sep 28

Transcode Therapeutics - Primary Endpoint of Phase 1a Study Met

THOMSON REUTERS
·
Sep 28

Transcode Therapeutics - Announces Patent Advancements in Australia and Japan for Rna Platform

THOMSON REUTERS
·
Sep 22

TransCode Therapeutics Says Australia Accepts Patent Application for siRNA Cancer Nanoparticle Delivery

Reuters
·
Sep 22

Transcode Therapeutics Names Interim CFO John A. Tattory in Initial Beneficial Ownership Filing

Reuters
·
Sep 22

TransCode Therapeutics Announces CFO Resignation and Interim Appointment

TIPRANKS
·
Sep 12

TransCode Therapeutics Appoints John Tattory as Interim CFO

Reuters
·
Sep 11

TransCode Therapeutics CFO Tom Fitzgerald Retires; John Tattory Named Interim CFO

Reuters
·
Sep 11

Transcode Therapeutics - Appoints John Tattory as Interim Chief Financial Officer Effective Immediately

THOMSON REUTERS
·
Sep 11

Transcode Therapeutics Announces Leadership Transition

THOMSON REUTERS
·
Sep 11

Press Release: TransCode Therapeutics Announces Leadership Transition

Dow Jones
·
Sep 11

TransCode Says Preclinical Study Shows Survival Benefit for TTX-MC138 in Breast Cancer Bone Metastasis Model

Reuters
·
Aug 31